Proteomic identification of biomarkers of skeletal muscle disorders

Biomarkers in Medicine

Volumn 7, Issue 1, 2013, Pages 169-186

  Ohlendieck, Kay ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

diabetes mellitus; electrostimulation; exercise; hypoxia; inclusion body myositis; motor neuron disease; muscular atrophy; muscular dystrophy; myotonia; sarcopenia

Indexed keywords

BIOLOGICAL MARKER; CREATINE KINASE; DYSFERLIN; DYSTROPHIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MUSCLE PROTEIN; MYOSIN LIGHT CHAIN 2; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

AGING; BLOOD ANALYSIS; CADAVER; CELLULAR DISTRIBUTION; DIABETES MELLITUS; ELECTROSTIMULATION THERAPY; EXERCISE; HIGH THROUGHPUT SCREENING; HUMAN; HYPOXIA; INCLUSION BODY MYOSITIS; MASS SPECTROMETRY; MOTOR NEURON DISEASE; MUSCLE ATROPHY; MUSCLE DISEASE; MUSCULAR DYSTROPHY; MYOPATHY; MYOTONIA; NEUROMUSCULAR DISEASE; NONHUMAN; OBESITY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SKELETAL MUSCLE;

BIOLOGICAL MARKERS; DIABETES MELLITUS; HUMANS; MOTOR NEURON DISEASE; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MUSCULAR DYSTROPHIES; MYOSITIS, INCLUSION BODY; MYOTONIA; OBESITY; PROTEOME; PROTEOMICS;

EID: 84873449631     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.96     Document Type: Review

References (148)

1. Laing NG. Genetics of neuromuscular disorders. Crit. Rev. Clin. Lab. Sci. 49, 33-48 (2012).
2. Malafarina V, Uriz-Otano F, Iniesta R, Gil-Guerrero L. Sarcopenia in the elderly: diagnosis, physiopathology and treatment. Maturitas 71, 109-114 (2012).
3. Shum AM, Polly P. Cancer cachexia: molecular targets and pathways for diagnosis and drug intervention. Endocr. Metab. Immune Disord. Drug Targets 12, 247-259 (2012).
4. Middlekauff HR. Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ. Heart Fail. 3, 537-546 (2010).
5. Roig M, Eng JJ, MacIntyre DL, Road JD, Reid WD. Deficits in muscle strength, mass, quality, and mobility in people with chronic obstructive pulmonary disease. J. Cardiopulm. Rehabil. Prev. 31, 120-124 (2011).
6. Smith IJ, Lecker SH, Hasselgren PO. Calpain activity and muscle wasting in sepsis. Am. J. Physiol. Endocrinol. Metab. 295, E762-E771 (2008).
7. Workeneh BT, Mitch WE. Review of muscle wasting associated with chronic kidney disease. Am. J. Clin. Nutr. 91, 1128S-1132S (2010).
8. Wells GD, Noseworthy MD, Hamilton J, Tarnopolski M, Tein I. Skeletal muscle metabolic dysfunction in obesity and metabolic syndrome. Can. J. Neurol. Sci. 35, 31-40 (2008).
9. Phielix E, Mensink M Type 2 diabetes mellitus and skeletal muscle metabolic function. Physiol. Behav. 94, 252-258 (2008).
10. Stephens NA, Gallagher IJ, Rooyackers O et al. Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. Genome Med. 2(1), 1 (2010).
11. Gillani S, Cao J, Suzuki T, Hak DJ. The effect of ischemia reperfusion injury on skeletal muscle. Injury 43, 670-675 (2012).
12. Brancaccio P, Lippi G, Maffulli N. Biochemical markers of muscular damage. Clin. Chem. Lab. Med. 48, 757-767 (2010).
13. Parekh R, Care DA, Tainter CR. Rhabdomyolysis: advances in diagnosis and treatment. Emerg. Med. Pract. 14, 1-15 (2012).
14. Chatzizisis YS, Misirli G, Hatzitolios AI, Giannoglou GD. The syndrome of rhabdomyolysis: complications and treatment. Eur. J. Intern. Med. 19, 568-574 (2008).
15. Brancaccio P, Maffulli N, Buonauro R, Limongelli FM. Serum enzyme monitoring in sports medicine. Clin. Sports Med. 27, 1-18 (2008).
16. Mendell JR, Shilling C, Leslie ND et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann. Neurol. 71, 304-313 (2012).
17. Väänänen HK, Takala TE, Tolonen U, Vuori J, Myllylä VV. Muscle-specific carbonic anhydrase III is a more sensitive marker of muscle damage than creatine kinase in neuromuscular disorders. Arch. Neurol. 45, 1254-1256 (1988).
18. Nie J, Tong TK, George K, Fu FH, Lin H, Shi Q. Resting and post-exercise serum biomarkers of cardiac and skeletal muscle damage in adolescent runners. Scand. J. Med. Sci. Sports 21, 625-629 (2011).
19. Reid MB, Moylan JS. Beyond atrophy: redox mechanisms of muscle dysfunction in chronic inflammatory disease. J. Physiol. 589, 2171-2179 (2011).
20. Linares LA, Golomb BA, Jaojoco JA, Sikand H, Phillips PS. The modern spectrum of rhabdomyolysis: drug toxicity revealed by creatine kinase screening. Curr. Drug Saf. 4, 181-187 (2009).
21. Tomaszewski M, Stpie KM, Tomaszewska J, Czuczwar SJ. Statin-induced myopathies. Pharmacol. Rep. 63, 859-866 (2011).
22. Stolcpart RS, Olson KL, Delate T, Rasmussen J, Rehring TF, Merenich JA. The risk for significant creatine kinase elevation with statins. Am. J. Cardiovasc. Drugs 10, 187-192 (2010).
23. Camerino GM, Pellegrino MA, Brocca L et al. Statin or fibrate chronic treatment modifies the proteomic profile of rat skeletal muscle. Biochem. Pharmacol. 81, 1054-1064 (2011).
24. Mikami T, Aoki M, Kimura T. The application of mass spectrometry to proteomics and metabolomics in biomarker discovery and drug development. Curr. Mol. Pharmacol. 5, 301-316 (2012).
25. Lescuyer P, Hochstrasser D, Rabilloud T. How shall we use the proteomics toolbox for biomarker discovery? J. Proteome Res. 6, 3371-3376 (2007).
26. Herrera G, Diaz L, Martinez-Romero A et al. Cytomics. A multiparametric, dynamic approach to cell research. Toxicol. In Vitro 21, 176-182 (2007).
27. Bernas T, Gregori G, Asem EK, Robinson JP. Integrating cytomics and proteomics. Mol. Cell. Proteomics 5, 2-13 (2006).
28. Valet G. Cytomics, the human cytome project and systems biology: top-down resolution of the molecular biocomplexity of organisms by single cell analysis. Cell Prolif. 38, 171-174 (2005).
29. Chen X, Velliste M, Murphy RF. Automated interpretation of subcellular patterns in fluorescence microscope images for location proteomics. Cytometry A 69, 631-640 (2006).
30. Stastna M, Van Eyk JE. Secreted proteins as a fundamental source for biomarker discovery. Proteomics 12, 722-735 (2012).
31. Calligaris D, Villard C, Lafitte D. Advances in top-down proteomics for disease biomarker discovery. J. Proteomics 74, 920-934 (2011).
32. Schirle M, Bantscheff M, Kuster B. Mass spectrometry-based proteomics in preclinical drug discovery. Chem. Biol. 19, 72-84 (2012).
33. Ohlendieck K. Proteomics of skeletal muscle differentiation, neuromuscular disorders and fiber aging. Expert Rev. Proteomics 7, 283-296 (2010).
34. Gelfi C, Vasso M, Cerretelli P. Diversity of human skeletal muscle in health and disease: contribution of proteomics. J. Proteomics 74, 774-795 (2011).
35. Ohlendieck K. Skeletal muscle proteomics: current approaches, technical challenges and emerging techniques. Skelet. Muscle 1(1), 6 (2011).
36. Lewis C, Carberry S, Ohlendieck K. Proteomic profiling of x-linked muscular dystrophy. J. Muscle Res. Cell. Motil. 30, 267-279 (2009).
37. Ohlendieck K. Pathobiochemical changes in diabetic skeletal muscle as revealed by mass-spectrometry-based proteomics. J. Nutr. Metab. 2012, 893876 (2012).
38. Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. Physiol. Rev. 91, 1447-1531 (2011).
39. Canepari M, Pellegrino MA, D'Antona G, Bottinelli R. Skeletal muscle fibre diversity and the underlying mechanisms. Acta Physiol. (Oxf.) 199, 465-476 (2010).
40. Ohlendieck K. Proteomic profiling of fast-to-slow muscle transitions during aging. Front. Physiol. 2, 105 (2011).
41. Doran P, Gannon J, O'Connell K, Ohlendieck K. Proteomic profiling of animal models mimicking skeletal muscle disorders. Proteomics Clin. Appl. 1, 1169-1184 (2007).
42. Metskas LA, Kulp M, Scordilis SP. Gender dimorphism in the exercise-naïve murine skeletal muscle proteome. Cell. Mol. Biol. Lett. 15, 507-516 (2010).
43. Oh TS, Choi JW, Choi DK, Mukherjee R, Liu H, Yun JW. Gender dimorphism in skeletal muscle proteome between lean and diet-induced obese rats. Cell. Physiol. Biochem. 28, 981-996 (2011).
44. Dimova K, Metskas LA, Kulp M, Scordilis SP. Skeletal muscle gender dimorphism from proteomics. J. Vis. Exp. 58, pii:3536 (2011).
45. Capitanio D, Vigano A, Ricci E, Cerretelli P, Wait R, Gelfi C. Comparison of protein expression in human deltoideus and vastus lateralis muscles using two-dimensional gel electrophoresis. Proteomics 5, 2577-2586 (2005).
46. Okumura N, Hashida-Okumura A, Kita K et al. Proteomic analysis of slow-and fast-twitch skeletal muscles. Proteomics 5, 2896-2906 (2005).
47. Gelfi C, Viganò A, De Palma S et al. 2-D protein maps of rat gastrocnemius and soleus muscles. a tool for muscle plasticity assessment. Proteomics 6, 321-340 (2006).
48. Hadrévi J, Hellström F, Kieselbach T, Malm C, Pedrosa-Domellöf F. Protein differences between human trapezius and vastus lateralis muscles determined with a proteomic approach. BMC Musculoskelet. Disord. 12, 181 (2011).
49. Drexler HC, Ruhs A, Konzer A et al. On marathons and sprints: an integrated quantitative proteomics and transcriptomics analysis of differences between slow and fast muscle fibers. Mol. Cell. Proteomics 11(6), M111.010801 (2012).
50. Højlund K, Yi Z, Hwang H et al. Characterization of the human skeletal muscle proteome by one-dimensional gel electrophoresis and HPLC-ESI-MS/MS. Mol. Cell. Proteomics 7, 257-267 (2008).
51. Picard M, Hepple RT, Burelle Y. Mitochondrial functional specialization in glycolytic and oxidative muscle fibers: tailoring the organelle for optimal function. Am. J. Physiol. Cell. Physiol. 302, C629-C941 (2012).
52. Parker KC, Walsh RJ, Salajegheh M et al. Characterization of human skeletal muscle biopsy samples using shotgun proteomics. J. Proteome Res. 8, 3265-3277 (2009).
53. Mate SE, Brown KJ, Hoffman EP. Integrated genomics and proteomics of the Torpedo californica electric organ: concordance with the mammalian neuromuscular junction. Skelet. Muscle 1(1), 20 (2011).
54. Henningsen J, Rigbolt KT, Blagoev B, Pedersen BK, Kratchmarova I. Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol. Cell. Proteomics 9, 2482-2496 (2010).
55. Chan CY, Masui O, Krakovska O et al. Identification of differentially regulated secretome components during skeletal myogenesis. Mol. Cell. Proteomics 10(5), M110.004804 (2011).
56. Lefort N, Yi Z, Bowen B et al. Proteome profile of functional mitochondria from human skeletal muscle using one-dimensional gel electrophoresis and HPLC-ESI-MS/MS. J. Proteomics 72, 1046-1060 (2009).
57. Ferreira R, Vitorino R, Alves RM et al. Subsarcolemmal and intermyofibrillar mitochondria proteome differences disclose functional specializations in skeletal muscle. Proteomics 10, 3142-3154 (2010).
58. Højlund K, Bowen BP, Hwang H et al. In vivo phosphoproteome of human skeletal muscle revealed by phosphopeptide enrichment and HPLC-ESI-MS/MS. J. Proteome Res. 8, 4954-4965 (2009).
59. Kodama S, Saito K, Tanaka S et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA 301, 2024-2035 (2009).
60. Burniston JG, Hoffman EP. Proteomic responses of skeletal and cardiac muscle to exercise. Expert Rev. Proteomics 8, 361-377 (2011).
61. Guelfi KJ, Casey TM, Giles JJ, Fournier PA, Arthur PG. A proteomic analysis of the acute effects of high-intensity exercise on skeletal muscle proteins in fasted rats. Clin. Exp. Pharmacol. Physiol. 33, 952-957 (2006).
62. Burniston JG. Changes in the rat skeletal muscle proteome induced by moderate-intensity endurance exercise. Biochim. Biophys. Acta 1784, 1077-1086 (2008).
63. Magherini F, Abruzzo PM, Puglia M et al. Proteomic analysis and protein carbonylation profile in trained and untrained rat muscles. J. Proteomics 75, 978-992 (2012).
64. Yamaguchi W, Fujimoto E, Higuchi M, Tabata I. A DIGE proteomic analysis for high-intensity exercise-trained rat skeletal muscle. J. Biochem. 148, 327-333 (2010).
65. Gandra PG, Valente RH, Perales J, Pacheco AG, Macedo DV. Proteomic profiling of skeletal muscle in an animal model of overtraining. Proteomics 12, 2663-2667 (2012).
66. Holloway KV, O'Gorman M, Woods P et al. Proteomic investigation of changes in human vastus lateralis muscle in response to interval-exercise training. Proteomics 9, 5155-5174 (2009).
67. Hody S, Leprince P, Sergeant K et al. Human muscle proteome modifications after acute or repeated eccentric exercises. Med. Sci. Sports Exerc. 43, 2281-2296 (2011).
68. Egan B, Dowling P, O'Connor PL et al. 2-D DIGE analysis of the mitochondrial proteome from human skeletal muscle reveals time course-dependent remodelling in response to 14 consecutive days of endurance exercise training. Proteomics 11, 1413-1428 (2011).
69. Norheim F, Raastad T, Thiede B, Rustan AC, Drevon CA, Haugen F. Proteomic identification of secreted proteins from human skeletal muscle cells and expression in response to strength training. Am. J. Physiol. Endocrinol. Metab. 301, E1013-E1021 (2011).
70. Malm C, Yu JG. Exercise-induced muscle damage and inflammation: re-evaluation by proteomics. Histochem. Cell Biol. 138, 89-99 (2012).
71. Scoppetta F, Tartaglia M, Renzone G et al. Plasma protein changes in horse after prolonged physical exercise. A proteomic study. J. Proteomics 75, 4494-4504 (2012).
72. Mesana TG, Mouly-Bandini A, Ferzoco SJ et al. Dynamic aortomyoplasty. clinical experience and thoracoscopic surgery feasibility study. J. Card. Surg. 13, 60-69 (1998).
73. Salmons S. Cardiac assistance from skeletal muscle: a reappraisal. Eur. J. Cardiothorac. Surg. 35, 204-213 (2009).
74. Karatzanos E, Gerovasili V, Zervakis D et al. Electrical muscle stimulation: an effective form of exercise and early mobilization to preserve muscle strength in critically ill patients. Crit. Care Res. Pract. 2012, 432752 (2012).
75. Vivodtzev I, Lacasse Y, Maltais F. Neuromuscular electrical stimulation of the lower limbs in patients with chronic obstructive pulmonary disease. J. Cardiopulm. Rehabil. Prev. 28, 79-91 (2008).
76. Karavidas A, Arapi SM, Pyrgakis V, Adamopoulos S. Functional electrical stimulation of lower limbs in patients with chronic heart failure. Heart Fail. Rev. 15, 563-579 (2010).
77. Ohlendieck K. Proteomic profiling of skeletal muscle plasticity. Muscle Lig. Tend. J. 1, 118-125 (2011).
78. Donoghue P, Doran P, Dowling P, Ohlendieck K. Differential expression of the fast skeletal muscle proteome following chronic low-frequency stimulation. Biochim. Biophys. Acta 1752, 166-176 (2005).
79. Donoghue P, Doran P, Wynne K, Pedersen K, Dunn MJ, Ohlendieck K. Proteomic profiling of chronic low-frequency stimulated fast muscle. Proteomics 7, 3417-3430 (2007).
80. Gondin J, Brocca L, Bellinzona E et al. Neuromuscular electrical stimulation training induces atypical adaptations of the human skeletal muscle phenotype. A functional and proteomic analysis. J. Appl. Physiol. 110, 433-450 (2011).
81. Burge JA, Hanna MG. Novel insights into the pathomechanisms of skeletal muscle channelopathies. Curr. Neurol. Neurosci. Rep. 12, 62-69 (2012).
82. Jurkat-Rott K, Lerche H, Weber Y, Lehmann-Horn F. Hereditary channelopathies in neurology. Adv. Exp. Med. Biol. 686, 305-334 (2010).
83. Lossin C, George AL Jr. Myotonia congenita. Adv. Genet. 63, 25-55 (2008).
84. Staunton L, Jockusch H, Ohlendieck K. Proteomic analysis of muscle affected by motor neuron degeneration: the wobbler mouse model of amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 406, 595-600 (2011).
85. Marimuthu K, Murton AJ, Greenhaff PL. Mechanisms regulating muscle mass during disuse atrophy and rehabilitation in humans. J. Appl. Physiol. 110, 555-560 (2011).
86. Moriggi M, Cassano P, Vasso M et al. DIGE approach for the assessment of rat soleus muscle changes during unloading. effect of acetyl-l-carnitine supplementation. Proteomics 8, 3588-3604 (2008).
87. Ferreira R, Vitorino R, Neuparth MJ, Appell HJ, Duarte JA, Amado F. Proteolysis activation and proteome alterations in murine skeletal muscle submitted to 1 week of hindlimb suspension. Eur. J. Appl. Physiol. 107, 553-556 (2009).
88. Moriggi M, Vasso M, Fania C et al. Long term bed rest with and without vibration exercise countermeasures: effects on human muscle protein dysregulation. Proteomics 10, 3756-3774 (2010).
89. Flueck M. Plasticity of the muscle proteome to exercise at altitude. High Alt. Med. Biol. 10, 183-193 (2009).
90. De Palma S, Ripamonti M, Vigano A et al. Metabolic modulation induced by chronic hypoxia in rats using a comparative proteomic analysis of skeletal muscle tissue. J. Proteome Res. 6, 1974-1984 (2007).
91. Vigano A, Ripamonti M, De Palma S et al. Proteins modulation in human skeletal muscle in the early phase of adaptation to hypobaric hypoxia. Proteomics 8, 4668-4679 (2008).
92. Bushby K, Finkel R, Birnkrant DJ et al. Diagnosis and management of Duchenne muscular dystrophy, part 1. Diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9, 77-93 (2010).
93. Lewis C, Ohlendieck K. Mass spectrometric identification of dystrophin isoform Dp427 by on-membrane digestion of sarcolemma from skeletal muscle. Anal. Biochem. 404, 197-203 (2010).
94. Yoon JH, Johnson E, Xu R, Martin LT, Martin PT, Montanaro F. comparative proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and galgt2 transgenic mouse skeletal muscle. J. Proteome Res. 11, 4413-4424 (2012).
95. Partridge TA. Impending therapies for Duchenne muscular dystrophy. Curr. Opin. Neurol. 24, 415-422 (2011).
96. Guevel L, Lavoie JR, Perez-Iratxeta C et al. Quantitative proteomic analysis of dystrophic dog muscle. J. Proteome Res. 10, 2465-2478 (2011).
97. Lewis C, Ohlendieck K. Proteomic profiling of naturally protected extraocular muscles from the dystrophin-deficient mdx mouse. Biochem. Biophys. Res. Commun. 396, 1024-1029 (2010).
98. Gardan-Salmon D, Dixon JM, Lonergan SM and Selsby JT. Proteomic assessment of the acute phase of dystrophin deficiency in mdx mice. Eur. J. Appl. Physiol. 111, 2763-2773 (2011).
99. Carberry S, Zweyer M, Swandulla D, Ohlendieck K. Profiling of age-related changes in the tibialis anterior muscle proteome of the mdx mouse model of dystrophinopathy. J. Biomed. Bioeng. 2012, 691641 (2012).
100. Carberry S, Zweyer M, Swandulla D, Ohlendieck K. Proteomics reveals drastic increase of extracellular matrix proteins collagen and dermatopontin in the aged mdx diaphragm model of Duchenne muscular dystrophy. Int. J. Mol. Med. 30, 229-234 (2012).
101. Doran P, Wilton SD, Fletcher S and Ohlendieck K. Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm. Proteomics 9, 671-685 (2009).
102. Greenberg SA, Salajegheh M, Judge DP et al. Etiology of limb girdle muscular dystrophy 1D/1E determined by laser capture microdissection proteomics. Ann. Neurol. 71, 141-145 (2012).
103. De Palma S, Morandi L, Mariani E et al. Proteomic investigation of the molecular pathophysiology of dysferlinopathy. Proteomics 6, 379-385 (2006).
104. De Morrée A, Hensbergen PJ, van Haagen HH et al. Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity. PLoS One 5, e13854 (2010).
105. Park SW, Goodpaster BH, Lee JS et al. Excessive loss of skeletal muscle mass in older adults with Type 2 diabetes. Diabetes Care 32, 1993-1997 (2009).
106. Andersen H. Motor dysfunction in diabetes. Diabetes Metab. Res. Rev. 28(Suppl. 1), 89-92 (2012).
107. Højlund K, Yi Z, Lefort N et al. Human ATP synthase beta is phosphorylated at multiple sites and shows abnormal phosphorylation at specific sites in insulin-resistant muscle. Diabetologia 53, 541-551 (2010).
108. Hwang H, Bowen BP, Lefort N et al. Proteomics analysis of human skeletal muscle reveals novel abnormalities in obesity and Type 2 diabetes. Diabetes 59, 33-42 (2010).
109. Lefort N, Glancy B, Bowen B et al. Increased reactive oxygen species production and lower abundance of complex I subunits and carnitine palmitoyltransferase 1B protein despite normal mitochondrial respiration in insulin-resistant human skeletal muscle. Diabetes 59, 2444-2452 (2010).
110. Mullen E, Ohlendieck K. Proteomic profiling of non-obese Type 2 diabetic skeletal muscle. Int. J. Mol. Med. 25, 445-458 (2010).
111. Mullen E, O'Reilly E, Ohlendieck K. Skeletal muscle tissue from the Goto-Kakizaki rat model of type-2 diabetes exhibits increased levels of the small heat shock protein Hsp27. Mol. Med. Rep. 4(2), 229-236 (2011).
112. Giebelstein J, Poschmann G, Højlund K et al. The proteomic signature of insulin-resistant human skeletal muscle reveals increased glycolytic and decreased mitochondrial enzymes. Diabetologia 55, 1114-1127 (2012).
113. Thingholm TE, Bak S, Beck-Nielsen H, Jensen ON, Gaster M. Characterization of human myotubes from Type 2 diabetic and nondiabetic subjects using complementary quantitative mass spectrometric methods. Mol. Cell. Proteomics 10(9), M110.006650 (2011).
114. Consitt LA, Bell JA, Houmard JA. Intramuscular lipid metabolism, insulin action, and obesity. IUBMB Life. 61, 47-55 (2009).
115. Hittel DS, Hathout Y, Hoffman EP, Houmard JA. Proteome analysis of skeletal muscle from obese and morbidly obese women. Diabetes 54, 1283-1288 (2005).
116. Wijers SL, Smit E, Saris WH et al. Cold-and overfeeding-induced changes in the human skeletal muscle proteome. J. Proteome Res. 9, 2226-2235 (2010).
117. Wood-Allum C, Shaw PJ. Motor neurone disease: a practical update on diagnosis and management. Clin. Med. 10, 252-258 (2010).
118. Otto M, Bowser R, Turner M et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph. Lateral Scler. 13, 1-10 (2012).
119. Ryberg H, An J, Darko S et al. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve 42, 104-111 (2010).
120. Staunton L, Jockusch H, Ohlendieck K. Proteomic analysis of muscle affected by motor neuron degeneration: the wobbler mouse model of amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 406, 595-600 (2011).
121. Schmitt-John T, Drepper C, Mussmann A et al. Mutation of Vps54 causes motor neuron disease and defective spermiogenesis in the wobbler mouse. Nat. Genet. 37, 1213-1215 (2005).
122. Wu CY, Whye D, Glazewski L et al. Proteomic assessment of a cell model of spinal muscular atrophy. BMC Neurosci. 12, 25 (2011).
123. Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J. Neurol. Neurosurg. Psychiatry 80, 1186-1193 (2009).
124. Li J, Yin C, Okamoto H et al. Proteomic analysis of inclusion body myositis. J. Neuropathol. Exp. Neurol. 65, 826-833 (2006).
125. Hutchinson DO, Jongbloed B. Two-dimensional gel electrophoresis in inclusion body myositis. J. Clin. Neurosci. 15, 440-444 (2008).
126. Parker KC, Kong SW, Walsh RJ et al. Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis. Muscle Nerve 39, 739-753 (2009).
127. Sela I, Milman Krentsis I, Shlomai Z et al. The proteomic profile of hereditary inclusion body myopathy. PLoS One 6, e16334 (2011).
128. Doppler K, Lindner A, Schütz W, Schütz M, Bornemann A. Gain and loss of extracellular molecules in sporadic inclusion body myositis and polymyositis-a proteomics-based study. Brain Pathol. 22, 32-40 (2012).
129. Thompson LV. Age-related muscle dysfunction. Exp. Gerontol. 44, 106-111 (2009).
130. Berger MJ, Doherty TJ. Sarcopenia: prevalence, mechanisms, and functional consequences. Interdiscip. Top. Gerontol. 37, 94-114 (2010).
131. Doran P, Donoghue P, O'Connell K, Gannon J, Ohlendieck K. Proteomics of skeletal muscle aging. Proteomics 9, 989-1003 (2009).
132. Gelfi C, Vigano A, Ripamonti M et al. The human muscle proteome in aging. J. Proteome Res. 5, 1344-1353 (2006).
133. Doran P, O'Connell K, Gannon J, Kavanagh M, Ohlendieck K. Opposite pathobiochemical fate of pyruvate kinase and adenylate kinase in aged rat skeletal muscle as revealed by proteomic DIGE analysis. Proteomics 8, 364-377 (2008).
134. O'Connell K, Ohlendieck K. Proteomic DIGE analysis of the mitochondria-enriched fraction from aged rat skeletal muscle. Proteomics 9, 5509-5524 (2009).
135. Donoghue P, Staunton L, Mullen E, Manning G, Ohlendieck K. DIGE analysis of rat skeletal muscle proteins using nonionic detergent phase extraction of young adult versus aged gastrocnemius tissue. J. Proteomics 73, 1441-1453 (2010).
136. Brulé C, Dargelos E, Diallo R et al. Proteomic study of calpain interacting proteins during skeletal muscle aging. Biochimie 92, 1923-1933 (2010).
137. Schoneich C. Protein modification in aging: an update. Exp. Gerontol. 41, 807-812 (2006).
138. Sharov VS, Schoneich C. Proteomic approach to aging research. Expert Rev. Proteomics 4, 309-321 (2007).
139. Kanski J, Alterman MA, Schoneich C. Proteomic identification of age-dependent protein nitration in rat skeletal muscle. Free Radic. Biol. Med. 35, 1229-1239 (2003).
140. Kanski J, Hong SJ, Schoneich C. Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine-containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry. J. Biol. Chem. 280, 24261-24266 (2005).
141. O'Connell K, Doran P, Gannon J, Ohlendieck K. Lectin-based proteomic profiling of aged skeletal muscle: decreased pyruvate kinase isozyme M1 exhibits drastically increased levels of N-glycosylation. Eur. J. Cell Biol. 87, 793-805 (2008).
142. Gannon J, Staunton L, O'Connell K, Doran P, Ohlendieck K. Phosphoproteomic analysis of aged skeletal muscle. Int. J. Mol. Med. 22, 33-42 (2008).
143. Gannon J, Doran P, Kirwan A, Ohlendieck K. Drastic increase of myosin light chain MLC-2 in senescent skeletal muscle indicates fast-to-slow fibre transition in sarcopenia of old age. Eur. J. Cell Biol. 88, 685-700 (2009).
144. Tavichakorntrakool R, Prasongwattana V, Sriboonlue P et al. Serial analyses of postmortem changes in human skeletal muscle. A case study of alterations in proteome profile, histology, electrolyte contents, water composition, and enzyme activity. Proteomics Clin. Appl. 2, 1255-1264 (2008).
145. Tavichakorntrakool R, Sriboonlue P, Prasongwattana V et al. Metabolic enzymes, antioxidants, and cytoskeletal proteins are significantly altered in vastus lateralis muscle of K-depleted cadaveric subjects. J. Proteome Res. 8, 2586-2593 (2009).
146. Jia X, Ekman M, Grove H et al. Proteome changes in bovine longissimus thoracis muscle during the early postmortem storage period. J. Proteome Res. 6, 2720-2731 (2007).
147. Paredi G, Raboni S, Bendixen E, de Almeida AM, Mozzarelli A. 'Muscle to meat' molecular events and technological transformations: the proteomics insight. J. Proteomics 75, 4275-4289 (2012).
148. Mallick P, Kuster B. Proteomics: a pragmatic perspective. Nat. Biotechnol. 28, 695-709 (2010).